Noninvasive methodology for assessing regional drug absorption from the gastrointestinal tract

Pharmaceutical Technology

Volumn 21, Issue 10, 1997, Pages 82-89

  Gardner, David ^a   Casper, Robert ^a   Leith, Frank ^a   Wilding, Ian ^b  

^a Innovative Devices LLC   (United States)

^b PHARMACEUTICAL PROFILES LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FUROSEMIDE; THEOPHYLLINE;

DRUG ABSORPTION; DRUG CAPSULE; DRUG DELIVERY SYSTEM; DRUG PENETRATION; GAMMA SCINTIGRAPHY; GASTROINTESTINAL ABSORPTION; METHODOLOGY; REVIEW;

EID: 0030779651     PISSN: 01478087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. S.P. Newman and I.R. Wilding, "The Importance of Gamma Scintigraphy in Pharmaceutical Development," J. Pharm. Med. 6, 21-33 (1996).
2. S.M. Hwang, W. Bayne, and F. Theeuwes, "In Vivo Evaluation of Controlled-Release Products," J. Pharm. Sci. 82 (11), 1145-1150 (1993).
3. S.S. Davis, "Overcoming Barriers to the Oral Administration of Peptide Drugs," Trends Pharma. Sci. 11, 353-355 (1990).
4. I.R. Wilding, S.S. Davis, and D.T. O'Hagan, "Targeting of Drugs and Vaccines to the Gut," Pharma. Ther. 62, 97-124 (1994).
5. M. Mackay and E. Tomlinson, "Colonic Delivery of Therapeutic Peptides and Proteins," in Colonic Drug Absorption and Metabolism, P.R. Bieck, Ed. (Marcel Dekker, New York, 1993), pp. 159-176.
6. T. Fujita et al., "Improvement of Intestinal Absorption of Human Calcitonin by Chemical Modifications with Fatty Acids: Synergistic Effects of Acylation and Absorption Enhancers," Int. J. Pharm. 134, 45-57 (1996).
7. P-Y. Yeh et al., "Site-Specific Drug Delivery and Penetration Enhancement in the Gastrointestinal Tract," J. Contr. Release 36, 109-124 (1995).
8. G.Y. Kwei et al., "Regiospecific Intestinal Absorption of the HIV Protease Inhibitor L-735.524 in Beagle Dogs," Pharm. Res. 12 (6), 884-888 (1995).
9. N. Rouge, P. Buri, and E. Doelker. "Drug Absorption Sites in the Gastrointestinal Tract and Dosage Forms for Site-Specific Delivery," Int. J. Pharm. 136, 117-139 (1996).
10. J.S. Fortran, "Segmental Perfusion Techniques," Gastroenterology 56, 987-989 (1969).
11. L. Knutson, B. Odlind, and R. Hullgren, "A New Technique for Segmental Jejunal Perfusion in Man," Am. J. Gastroent. 84 (10), 1278-1284 (1989).
12. H. Lennernäs et al., "Regional Jejunal Perfusion, A New In Vivo Approach to Study Oral Drug Absorption in Man," Pharm. Res. 9 (10), 1243-1251 (1992).
13. W.H. Barr et al., "Differential Absorption of Amoxicillin from the Human Small and Large Intestine," Clin. Pharmacol. Ther. 56 (3), 279-285 (1994).
14. K.K. Chan et al., "Site-Differential Gastrointestinal Absorption of Benazepril Hydrochloride in Healthy Volunteers," Pharm. Res. 11 (3), 432-437 (1994).
15. N. Vidon et al., "Evaluation of the Gastric Absorption and Emptying of Drugs under Various pH Conditions Using a Simple Intubation Method: Application to Diclofenac," Br. J. Clin. Pharm. 28 (1), 121-124(1989).
16. V.S. Chadwick, S.F. Phillips, and A.F. Hoffmann, "Measurement of Intestinal Permeability Using Low Molecular Weight Polyethylene Glycols (PEG 400)," Gastroenterology 73, 247-251 (1977).
17. N.W. Read et al., "Effect of Gastrointestinal Intubation on the Passage of a Solid Meal through the Stomach and Small Intestine in Humans," Gastroenterology 84, 1568-1572 (1983).
18. K-H. Antonin, "Other Methods in Studying Colonic Drug Absorption," in Colonic Drug Absorption and Metabolism, P.R. Bieck, Ed. (Marcel Dekker, New York, 1993), pp. 89-107.
19. U. Fuhr et al., "Absorption of Ipsapirone Along the Human Gastrointestinal Tract," Br. J. Clin. Pharm. 38 (1), 83-86 (1994).
20. S. Harder et al., "Ciprofloxacin Absorption in Different Regions of the Human Gastrointestinal Tract. Investigations with the HF Capsule," Br. J. Clin. Pharm. 30 (1), 35-39 (1990).
21. A.H. Staib et al., "Measurement of Theophylline Absorption from Different Regions of the Gastrointestinal Tract Using a Remote Controlled Drug Delivery Device," Eur. J. Clin. Pharm. 30 (6), 691-697 (1986).
22. E.H. Graul, D. Loew, and O. Schuster, "Voraussetzung für die Entwicklung einer sinvollen Retard- und Diuretikakombination," Therapiewoche 35, 4277-4291 (1985).
23. H. Bode et al., "Investigation of Nifedipine Absorption in Different Regions of the Human Gastrointestinal (GI) Tract After Simultaneous Administration of 13C-and 12C-nifedipine," Eur. J. Clin. Pharmacol. 50, 195-201 (1996).
24. P.R. Bieck, "Drug Absorption from the Colon," in Drug Delivery to the Gastrointestinal Tract, J.G. Hardy, S.S. Davis, and C.G. Wilson, Eds. (Ellis Horwood, Chichester, UK, 1989), pp. 147-159.
25. US Patent 5167626, 5170801.
26. I.R. Wilding, A.J. Coupe, and S.S. Davis, "The Role of Gamma Scintigraphy in Oral Drug Delivery," Adv. Drug Del. Rev. 7, 87-117 (1991).
27. C. Nick, "Formulations on Trial," Good Clinical Practice 3 (5), 20-26 (1996).
28. G. Meseguer, R. Gurny, and P. Buri, "In Vivo Behaviour of Dosage Forms: Application of Gamma Scintigraphy to Non-Enterai Routes of Administration," J. Drug Target. 2, 269-288 (1994).
29. S.S. Davis et al., "Gamma Scintigraphy in the Evaluation of Pharmaceutical Dosage Forms," Eur. J. Nucl. Med. 19, 971-986 (1992).
30. L.G.J. De Leeds et al., "Zero-Order Rectal Delivery of Theophylline in Man with an Osmotic System," J. Pharmacokinet. Biopharm. 10 (5), 525-537 (1982).
31. S.A. Riley et al., "Absorption of Polar Drugs Following Caecal Instillation in Healthy Volunteers," Aliment. Pharmacol. Ther. 6, 701-706 (1992).
32. G.L. Amidon et al., "Theoretical Considerations in the Correlation of In Vitro Drug Product Dissolution and In Vivo Bioavailability; a Basis for a Biopharmaceutics Drug Classification," Pharm. Res. 12, 413-420 (1995).
33. A.S. Hussain et al., "Analysis of NDA and ANDA Database for Validation," Eur. J. Pharm. Sci. 5 Suppl. 2, S43-S44 (1997).